Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05979909 |
Recruitment Status :
Not yet recruiting
First Posted : August 7, 2023
Last Update Posted : August 7, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Urothelial Carcinoma Ureter Urothelial Cancer of Renal Pelvis | Drug: Mitomycin C | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Preventing Intravesical Recurrence in Patients With Urothelial Carcinoma of the Upper Urinary Tract: a Pilot Randomized Trial of a Single Prophylactic Bladder Instillation of Mitomycin C After Diagnostic Ureteroscopy |
Estimated Study Start Date : | September 2023 |
Estimated Primary Completion Date : | September 2025 |
Estimated Study Completion Date : | September 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Intravesical mitomycin C (MMC) |
Drug: Mitomycin C
Mitomycin (40 mg in 40 mL of sterile water) will be administered through a Foley catheter, which will be clamped for two hours. |
No Intervention: No intervention |
- Recruitment rate [ Time Frame: 30 days ]Proportion of patients who consent to participate in the study after being invited to do so
- Randomization rate [ Time Frame: 30 days ]Proportion of consented patients who are deemed eligible to participate and are randomly allocated to one of the two arms
- Retention rate [ Time Frame: 2 years ]Proportion of randomized patients who complete follow-up
- Adverse events (any) [ Time Frame: 30 days ]Cumulative incidence of adverse events
- Adverse events (severe) [ Time Frame: 30 days ]Cumulative incidence of grade 3-5 adverse events
- Intravesical recurrence [ Time Frame: 2 years ]Cumulative incidence of urothelial carcinoma of the bladder
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Suspected upper tract urothelial carcinoma (UTUC)
- Diagnostic ureteroscopy required
- Tumor suggestive of upper tract urothelial carcinoma (UTUC) found on ureteroscopy
Exclusion Criteria:
- Prior or concomitant urothelial carcinoma of the bladder
- History of UTUC
- Ureteroscopy within the preceding six months
- Untreated urinary tract infection
- Suspected or confirmed perforation of the upper or lower urinary tract
- Lower urinary tract fistula
- Leukopenia or thrombocytopenia
- ECOG performance status 2 or greater
- Known hypersensitivity to mitomycin C
- Pregnancy or breastfeeding
- Lack of capacity to consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05979909
Contact: Piotr Zareba, MD MPH | (905) 521-2100 ext 47109 | zareba@hhsc.ca |
Responsible Party: | McMaster University |
ClinicalTrials.gov Identifier: | NCT05979909 |
Other Study ID Numbers: |
14728 |
First Posted: | August 7, 2023 Key Record Dates |
Last Update Posted: | August 7, 2023 |
Last Verified: | July 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma Carcinoma, Transitional Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Mitomycins Mitomycin |
Antibiotics, Antineoplastic Antineoplastic Agents Alkylating Agents Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors |